Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans

HIV Medicine

Volumn 13, Issue 4, 2012, Pages 193-201

  Nanzigu, S ^a,b   Eriksen, J ^b,d   Makumbi, F ^a   Lanke, S ^c   Mahindi, M ^b   Kiguba, R ^a   Beck, O ^b   Ma, Q ^c   Morse, G D ^c   Gustafsson, L L ^b   Waako, P ^a  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY AT BUFFALO   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Autoinduction; Efavirenz; Pharmacokinetics; Ugandans

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CREATININE; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DYSPEPSIA; ETHNIC DIFFERENCE; EVENING DOSAGE; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEGRO; NEUROTOXICITY; POPULATION RESEARCH; PRIORITY JOURNAL; STEADY STATE; UGANDA; VIRUS LOAD;

ADULT; AREA UNDER CURVE; BENZOXAZINES; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; UGANDA; YOUNG ADULT;

EID: 84858002034     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00952.x     Document Type: Article

References (36)

1. Tseng A, Foisy M. Selected Properties of Efavirenz, 2010. Available at (accessed 14 February 2011).
2. Brundage RC, Yong FH, Fenton T, Spector SA, Starr SE, Fletcher CV. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 2004; 48: 979-984.
3. Burger D, van der Heiden I, Porte CLet al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2005; 61: 148-154.
4. *6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008; 64: 357-365.
5. Pereira SA, Branco T, Caixas Uet al. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy. Ther Drug Monit 2008; 30: 60-66.
6. Nettles RE, Kieffer TL, Parsons Tet al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42: 1189-1196.
7. *6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009; 68: 690-699.
8. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M.Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother 2009; 53: 2346-2353.
9. Ribaudo H, Clifford D, Gulick Ret al Relationships between Efavirenz Pharmacokinetics, Side Effects, Drug Discontinuation, Virologic Response, and Race: Results from ACTG A5095/A5097s. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 132].
10. Pfister M, Labbe L, Hammer SMet al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. J Antimicrob Chemother 2003; 47: 130-137.
11. Mukonzo JK, Nanzigu S, Rekic Det al. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet 2011; 50: 531-540.
12. *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV- infected patients. Br J Clin Pharmacol 2009; 67: 427-436.
13. Ward BA, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300.
14. Wyen C, Hendra H, Vogel Met al. Impact of CYP2B6 983 T >C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patient. J Antimicrob Chemother 2008; 61: 914-918.
15. Haas DW, Ribaudo HJ, Kim RBet al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-2400.
16. Kappelhoff BS, Huitema AD, Yalvac Zet al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1- infected individuals. Clin Pharmacokinet 2005; 44: 849-861.
17. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 1192-1194.
18. Leth FV, Kappelhoff BS, Johnson Det al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006; 22: 232-239.
19. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009; 64: 910-928.
20. WHO Toxicity Grading Scale for Determining The Severity of Adverse Events. Available at (accessed 20 June 2011).
21. Nanzigu S, Waako P, Petzold Met al. CD4-T-Lymphocyte reference ranges in Uganda and its influencing factors. J Lab Med 2011; 42: 94-101.
22. ® (efavirenz) capsules and tablets. Revised February 2005: 30-40.
23. Kappelhoff BS, van Leth F, MacGregor TR, Lange JMA, Beijnen JH, Huitema ADR for the 2NN study group. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antiviral Ther 2005; 10: 145-155.
24. Lopez-Cortes LF, Ruiz-Morales J, Leon Eet al. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother 2006; 58: 1017-1023.
25. Pereira SA, Caixas U, Branco Tet al. Does HCV or HBV infection influence efavirenz plasma concentrations in HIV-infected patients with well-compensated disease? 8th International Workshop on Pharmacology of HIV Therapy. Budapest, Hungary, April 2007 [Abstract 4].
26. Pereira SA, Caixas U, Branco Tet al. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br J Clin Pharmacol 2008; 66: 551-555.
27. Almond LM, Hoggard PG, Edirisinghe D, Khoo SH, Back DJ. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-744.
28. Molla A, Vasavanonda S, Kumar Get al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998; 250: 255-262.
29. International AIDS Society-USA. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. HIV Med 2003; 11: 40-44.
30. Mathias AA, Hinkle J, Menning M, Hui J, Kaul S, Kearney BPfor the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen Development Team. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr 2007; 46: 167-173.
31. Ma Q, Forrest A, Rosenkranz SLet al. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 2008; 29: 91-101.
32. Ngaimisi E, Mugusi S, Minzi OMet al. Long-term efavirenz auto induction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88: 676-684.
33. Calmy A, Hirschel B, Cooper DA, Carry A.A new era of antiretroviral drug toxicity. Antiviral Ther 2009; 14: 165-179.
34. Hasse B, Gunthard HF, Bleiber G, Krause M. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 2005; 40: e22-e23.
35. Ma Q, Smith PF, DiCenzo R, Judianne CS, Forrest A, Morse GD. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005; 1: 473-485.
36. Stohr W, Back D, Dunn Det al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antiviral Ther 2008; 13: 675-685.